Annovis is at the forefront, testing buntanetap in pivotal clinical trials as a therapy for Alzheimer's and Parkinson's diseases (PD). Company has filed three new patents protecting combinations of ...

Currently, there are four oral PDE5 inhibitors available in the United States for the treatment of ED: sildenafil (Viagra, Pfizer), vardenafil ... (donanemab-azbt, 350 mg/20 mL once-monthly ...

Brand-name Viagra is also available through Roman in 25-, 50-, or 100-mg pills for $90 per dose ... as Viagra but comes at a lower cost. While Pfizer still manufactures the “little blue pill ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

Pfizer shares have gained ground since a report over the weekend said that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes. Monitor ...

We came across a bullish thesis on Pfizer Inc. (PFE) on gurufocus by Akim Guerreiro. In this article we will summarize the bulls’ thesis on PFE. Pfizer Inc. share was trading at $29.16 as of ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The ...

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, emboldening the Big Pharma to target a 2025 start date for its pivotal ...

Pfizer is a global pharmaceutical giant with ... the company's payout ratio closer to its historical average of around 50%. While nothing is guaranteed in investing, the market's pessimistic ...